SC 006

Drug Profile

SC 006

Alternative Names: SC-006

Latest Information Update: 03 Feb 2017

Price : $50

At a glance

  • Originator AbbVie
  • Developer AbbVie; Stemcentrx
  • Class Antineoplastics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Colorectal cancer

Most Recent Events

  • 23 Jan 2017 AbbVie and Stemcentrx plan a phase I trial for Colorectal cancer (In adults, In the elderly, Refractory metastatic disease) in USA (NCT03035279)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top